CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of the central nervous system

Ţilea, Brînduşa; Voidăzan, Septimiu; Bălaşa, Rodica; Huţanu, Adina; Fodor, A.

doi:10.1515/rrlm-2016-0043

Cited by 1 publication

(1 citation statement)

References 28 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is for this reason that we had to define cut-off points for neopterin and CXCL-13 above which patients are considered non-stage 1; all patients with values below these thresholds are thus stage 1. According to the literature, the normal concentration of neopterin is less than 5.1 nmol/L of CSF [19], and the normal concentration of CXCL-13 is less than 11.5 pg/mL of CSF [59], but we do not know the true concentration values for these two biomarkers in healthy Angolan individuals. In our study, cut-off values (as well as their sensitivities and specificities) were defined on a limited sample size.…”

Section: Discussionmentioning

confidence: 99%

Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola

Bonnet

Vignoles

Tiberti

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Human African Trypanosomiasis may become manageable in the next decade with fexinidazole. However, currently stage diagnosis remains difficult to implement in the field and requires a lumbar puncture. Our study of an Angolan cohort of T. b. gambiense-infected patients used other staging criteria than those recommended by the WHO. We compared WHO criteria (cell count and parasite identification in the CSF) with two biomarkers (neopterin and CXCL-13) which have proven potential to diagnose disease stage or relapse. Biological, clinical, and neurological data were analysed from a cohort of 83 patients. A neopterin concentration below 15.5 nmol/L in the CSF denoted patients with stage 1 disease, and a concentration above 60.31 nmol/L characterized patients with advanced stage 2 (trypanosomes in CSF and/or cytorachia higher than 20 cells) disease. CXCL-13 levels below 91.208 pg/mL denoted patients with stage 1 disease, and levels of CXCL-13 above 395.45 pg/mL denoted patients with advanced stage 2 disease. Values between these cut-offs may represent patients with intermediate stage disease. Our work supports the existence of an intermediate stage in HAT, and CXCL-13 and neopterin levels may help to characterize it.

show abstract

Section: Discussionmentioning

confidence: 99%

Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola

Bonnet

Vignoles

Tiberti

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of the central nervous system

Abstract: Background: During the acute inflammatory process, the CXCL13 chemokine plays an important role in B cell recruitment within the central nervous system (CNS

Cited by 1 publication

References 28 publications

Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola

Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola

Contact Info

Product

Resources

About